Leveraging a disulfidptosis/ferroptosis-based signature to predict the prognosis of lung adenocarcinoma.

Ma, Xiaoqing; Deng, Zilin; Li, Zhen; Ma, Ting; Li, Guiqing; Zhang, Cuijia; Zhang, Wentao; Chang, Jin

Ma, Xiaoqing; Deng, Zilin; Li, Zhen; Ma, Ting; Li, Guiqing; Zhang, Cuijia; Zhang, Wentao; Chang, Jin.

Afiliação

Ma X; Department of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Deng Z; Shandong First Medical University, Jinan, Shandong, China.
Li Z; Department of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Ma T; Shandong First Medical University, Jinan, Shandong, China.
Li G; Department of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Zhang C; Shandong First Medical University, Jinan, Shandong, China.
Zhang W; Department of Radiation Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Chang J; Shandong First Medical University, Jinan, Shandong, China.

Cancer Cell Int ; 23(1): 267, 2023 Nov 09.

Article em En | MEDLINE | ID: mdl-37946181

Palavras-chave

Disulfidptosis; Ferroptosis; LUAD; Prognosis; Signature

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancer Cell Int Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China